05May 2024
Enhancing Antiplatelet Strategy in High-Risk PCI Patients with Peripheral Artery Disease: Insights From TWILIGHT Trial

Enhancing Antiplatelet Strategy in High-Risk PCI Patients with Peripheral Artery Disease: Insights From TWILIGHT Trial

A comparative analysis involving 7,119 patients undergoing percutaneous coronary intervention (PCI) scrutinized the efficacy of ticagrelor monotherapy versus ticagrelor with aspirin among those with peripheral artery disease (PAD). PAD patients, constituting 7% of the cohort, were older with more comorbidities and multivessel disease. Results showed ticagrelor monotherapy significantly reduced bleeding events (BARC 2, 3, or 5) compared to ticagrelor plus aspirin in both PAD and non-PAD groups. Importantly, PAD patients on monotherapy didn't experience increased ischemic events. This suggests ticagrelor monotherapy post-PCI may offer favorable outcomes in PAD patients, mitigating bleeding risks without raising ischemic event concerns.

  • #general medicine

Like

Save

Share